Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
| Autor: | X. Tsiafaki, E. Papadakis, Sophia Agelaki, Ageliki Rapti, Nikos Androulakis, C. Kalofonos, N. Vardakis, E. Bania, Ch. Kouroussis, V. Georgoulias, E. Sarra, M. Toubis, Kyriakos Chainis, S. Kakolyris |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms Neutropenia Paclitaxel medicine.medical_treatment Docetaxel Deoxycytidine Gastroenterology Disease-Free Survival Drug Administration Schedule Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Mucositis Humans Life Tables Survival rate Aged Salvage Therapy Chemotherapy Performance status business.industry Middle Aged medicine.disease Hematologic Diseases Survival Analysis Gemcitabine Chemotherapy regimen Recombinant Proteins Surgery Survival Rate Regimen Treatment Outcome Oncology Drug Resistance Neoplasm Disease Progression Female Taxoids Cisplatin business medicine.drug |
| Zdroj: | Lung Cancer. 32:179-187 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/s0169-5002(00)00212-9 |
| Popis: | Background: Docetaxel in combination with gemcitabine is an active front-line chemotherapy regimen against non-small cell lung cancer (NSCLC) with acceptable toxicity. A multicenter phase II study was conducted in order to determine the toxicity and efficacy of this combination, as salvage treatment in patients progressing after a cisplatin-based front line regimens. Patients and methods: Thirty-two patients with histologically confirmed, bidimensionally measurable NSCLC, who failed prior cisplatin-based chemotherapy were enrolled. The patients’ median age was 62.5 years, 29 (91%) were male, 23 (72%) had disease stage IV, and 22 (69%) had a performance status (WHO) 0–1. Gemcitabine (900 mg/m 2) was administered on days 1 and 8 and docetaxel (100 mg/m 2 ) on day 8, after appropriate premedication. rhG-CSF (150 μg/m 2 ) was given prophylactically from day 9 to 15. Treatment was repeated on an outpatient basis every three weeks. Results: A total of 127 chemotherapy cycles were administered. In an intention-to-treat analysis five patients (15.6%; 95% CI: 3.04–28.21%) achieved a partial response, 11 (34.4%) stable disease, and 16 (50%) progressive disease. The median duration of response was 9 months, the median TTP 7 months, and the overall median survival 6.5 months; the overall 1-year survival probability was 27.6%. Grade 3/4 neutropenia was observed in five (15.6%) patients and in two of them associated with fever. Grade 3 anemia and thrombocytopenia occurred in three (9%) and two (6.5%) patients, respectively. Non-hematologic toxicity was very mild with only one episode of grade 4 diarrhea and mucositis, respectively; two (6%) patients complained for grade 3 asthenia. Conclusion: The combination of gemcitabine and docetaxel with prophylactic use of rhG-CSF is a safe and well-tolerated regimen for the treatment of patients with advanced NSCLC, who failed front-line treatment with cisplatin-based regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect